HC Wainwright & Co. Downgrades Neovasc to Neutral

HC Wainwright & Co. analyst Vernon Bernardino downgrades Neovasc (NASDAQ:NVCN) from Buy to Neutral.

byBenzinga Newsdesk

January 18, 2023

1 minute read

HC Wainwright & Co. analyst Vernon Bernardino downgrades Neovasc (NASDAQ:NVCN) from Buy to Neutral.

Roth Capital Initiates Coverage On Unicycive Therapeutics with Buy Rating, Announces Price Target of $13.5

By Benzinga Newsdesk

Today, 4:18 PM

Roth Capital analyst Elemer Piros initiates coverage on Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and announces Price Target of $13.5.

UNCY

Analyst Ratings

BTIG Maintains Buy Rating for Enact Holdings: Here’s What You Need To Know

By Benzinga Insights

Today, 4:18 PM

BTIG has decided to maintain its Buy rating of Enact Holdings (NASDAQ:ACT) and lower its price target from $28.00 to $27.00. Shares of Enact Holdings are trading down 0.05% over the last 24 hours, at $21.65 per share. A move to $27.00 would account for a 24.71% increase from the current share price.

ACT

Morgan Stanley Downgrades Aptiv to Equal-Weight, Lowers Price Target to $105

By Benzinga Newsdesk

Today, 4:18 PM

Morgan Stanley analyst Adam Jonas downgrades Aptiv (NYSE:APTV) from Overweight to Equal-Weight and lowers the price target from $120 to $105.

APTV

Nasdaq Jumps Over 200 Points; GitLab Shares Plummet

By Lisa Levin

Today, 4:18 PM

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 400 points on Tuesday. The Dow traded up 1.30% to 32,234.35 while the NASDAQ rose 2.07% to 11,421.23. The S&P 500, also rose, gaining, 1.85% to 3,927.19.

AIMD

HC Wainwright & Co. Downgrades Neovasc to Neutral

Related Posts

Roth Capital Initiates Coverage On Unicycive Therapeutics with Buy Rating, Announces Price Target of $13.5

BTIG Maintains Buy Rating for Enact Holdings: Here’s What You Need To Know

Morgan Stanley Downgrades Aptiv to Equal-Weight, Lowers Price Target to $105

Nasdaq Jumps Over 200 Points; GitLab Shares Plummet